249 related articles for article (PubMed ID: 11416111)
1. Reovirus as an oncolytic agent against experimental human malignant gliomas.
Wilcox ME; Yang W; Senger D; Rewcastle NB; Morris DG; Brasher PM; Shi ZQ; Johnston RN; Nishikawa S; Lee PW; Forsyth PA
J Natl Cancer Inst; 2001 Jun; 93(12):903-12. PubMed ID: 11416111
[TBL] [Abstract][Full Text] [Related]
2. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
3. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.
Lun X; Yang W; Alain T; Shi ZQ; Muzik H; Barrett JW; McFadden G; Bell J; Hamilton MG; Senger DL; Forsyth PA
Cancer Res; 2005 Nov; 65(21):9982-9990. PubMed ID: 16267023
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.
Yang WQ; Lun X; Palmer CA; Wilcox ME; Muzik H; Shi ZQ; Dyck R; Coffey M; Thompson B; Hamilton M; Nishikawa SG; Brasher PM; Fonseca K; George D; Rewcastle NB; Johnston RN; Stewart D; Lee PW; Senger DL; Forsyth PA
Clin Cancer Res; 2004 Dec; 10(24):8561-76. PubMed ID: 15623640
[TBL] [Abstract][Full Text] [Related]
5. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma.
Yang WQ; Senger D; Muzik H; Shi ZQ; Johnson D; Brasher PM; Rewcastle NB; Hamilton M; Rutka J; Wolff J; Wetmore C; Curran T; Lee PW; Forsyth PA
Cancer Res; 2003 Jun; 63(12):3162-72. PubMed ID: 12810644
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic reovirus against ovarian and colon cancer.
Hirasawa K; Nishikawa SG; Norman KL; Alain T; Kossakowska A; Lee PW
Cancer Res; 2002 Mar; 62(6):1696-701. PubMed ID: 11912142
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
[TBL] [Abstract][Full Text] [Related]
9. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir.
Markert JM; Malick A; Coen DM; Martuza RL
Neurosurgery; 1993 Apr; 32(4):597-603. PubMed ID: 8386343
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway.
Fueyo J; Alemany R; Gomez-Manzano C; Fuller GN; Khan A; Conrad CA; Liu TJ; Jiang H; Lemoine MG; Suzuki K; Sawaya R; Curiel DT; Yung WK; Lang FF
J Natl Cancer Inst; 2003 May; 95(9):652-60. PubMed ID: 12734316
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model.
Kawaguchi K; Etoh T; Suzuki K; Mitui MT; Nishizono A; Shiraishi N; Kitano S
Int J Oncol; 2010 Dec; 37(6):1433-8. PubMed ID: 21042711
[TBL] [Abstract][Full Text] [Related]
13. All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma.
Alloussi SH; Alkassar M; Urbschat S; Graf N; Gärtner B
Oncol Rep; 2011 Sep; 26(3):645-9. PubMed ID: 21637921
[TBL] [Abstract][Full Text] [Related]
14. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.
Yang WQ; Senger DL; Lun XQ; Muzik H; Shi ZQ; Dyck RH; Norman K; Brasher PM; Rewcastle NB; George D; Stewart D; Lee PW; Forsyth PA
Gene Ther; 2004 Nov; 11(21):1579-89. PubMed ID: 15372068
[TBL] [Abstract][Full Text] [Related]
15. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
[TBL] [Abstract][Full Text] [Related]
16. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
[TBL] [Abstract][Full Text] [Related]
17. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
18. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.
Ogbomo H; Zemp FJ; Lun X; Zhang J; Stack D; Rahman MM; McFadden G; Mody CH; Forsyth PA
PLoS One; 2013; 8(6):e66825. PubMed ID: 23762498
[TBL] [Abstract][Full Text] [Related]
19. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
[TBL] [Abstract][Full Text] [Related]
20. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
Shah AC; Price KH; Parker JN; Samuel SL; Meleth S; Cassady KA; Gillespie GY; Whitley RJ; Markert JM
J Virol; 2006 Aug; 80(15):7308-15. PubMed ID: 16840311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
